• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Aminosaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Aminosaccharides

Isepamicin Sulfate (CAS No. 67814-76-0): An Overview of a Promising Antibiotic

Isepamicin sulfate (CAS No. 67814-76-0) is a semi-synthetic aminoglycoside antibiotic derived from the natural product micronomicin. This compound has gained significant attention in the pharmaceutical industry due to its potent antibacterial activity and potential for treating multidrug-resistant infections. In this comprehensive overview, we will delve into the chemical structure, pharmacological properties, clinical applications, and recent research developments surrounding isepamicin sulfate.

The chemical structure of isepamicin sulfate is characterized by its aminoglycoside backbone, which is responsible for its broad-spectrum antibacterial activity. The compound is composed of a deoxystreptamine nucleus with several functional groups that enhance its binding affinity to bacterial ribosomes. This structural feature allows isepamicin sulfate to inhibit protein synthesis in bacteria, making it an effective agent against both gram-positive and gram-negative pathogens.

In terms of pharmacokinetics, isepamicin sulfate exhibits favorable properties that contribute to its therapeutic efficacy. It is rapidly absorbed after intramuscular or intravenous administration and distributes widely throughout the body. The drug has a relatively short half-life, which necessitates multiple daily dosing regimens. However, this short half-life also reduces the risk of accumulation and potential toxicity. Recent studies have shown that the pharmacokinetic profile of isepamicin sulfate can be optimized through various formulations, such as liposomal delivery systems, to enhance its therapeutic window and reduce side effects.

Clinically, isepamicin sulfate has been evaluated for its effectiveness in treating a range of infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections. Its ability to combat multidrug-resistant bacteria has made it particularly valuable in settings where conventional antibiotics are less effective. A recent meta-analysis published in the Journal of Antimicrobial Chemotherapy highlighted the superior efficacy of isepamicin sulfate compared to other aminoglycosides in treating multidrug-resistant gram-negative infections.

The safety profile of isepamicin sulfate has also been extensively studied. While all aminoglycosides carry the risk of nephrotoxicity and ototoxicity, isepamicin sulfate has demonstrated a more favorable safety profile compared to older agents like gentamicin and tobramycin. Clinical trials have shown that the incidence of adverse effects is generally low when isepamicin sulfate is used at recommended doses and for short durations. However, careful monitoring of renal function and auditory function is still recommended during treatment.

In addition to its clinical applications, recent research has explored the potential of isepamicin sulfate in combination therapy with other antibiotics to combat drug-resistant bacteria. A study published in the International Journal of Antimicrobial Agents investigated the synergistic effects of isepamicin sulfate^sulfate?(^{CAS?No.?67814-76-0)?with?beta-lactam?antibiotics?such?as?meropenem.?The?results?demonstrated?that?the?combination?therapy?significantly?enhanced?bactericidal?activity?against?Pseudomonas aeruginosa?and?Klebsiella pneumoniae,?two?notable?multipledrug-resistant pathogens.}

Beyond its immediate clinical applications, there is ongoing research into the mechanisms by which isepamicin sulfate exerts its antibacterial effects. A study published in the Journal of Medicinal Chemistry identified specific binding sites on bacterial ribosomes where isepamicin sulfate interacts to inhibit protein synthesis. Understanding these molecular interactions could lead to the development of novel derivatives with enhanced activity and reduced toxicity.

In conclusion, Isepamicin sulfate (CAS No. 67814-76-0) represents a promising antibiotic with significant potential for treating multidrug-resistant infections. Its favorable pharmacokinetic profile, broad-spectrum activity, and improved safety compared to older aminoglycosides make it an attractive option for clinicians. Ongoing research into combination therapy and molecular mechanisms will likely further enhance its therapeutic value in the future.

• 149022-22-0(Amikacin Sulfate Salt)
• 39831-55-5(Amikacin Disulfate)
• 104931-87-5(Arbekacin Sulfate (Technical Grade))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)